Skip to main content
TB-500 MD

A modular research dossier on TB-500 — the Ac-LKKTETQ fragment of thymosin beta-4 — tiling each muscle, tendon, and regulatory finding into its own panel, with the human-data gaps and the full-length-versus-fragment caveat surfaced in plain view.

FAQ / 06

TB-500, answered tile by tile

Twenty-five questions on the thymosin beta-4 fragment — each answer direct, cited, and honest about where the data are for the full-length protein.

Read the researchLegal status & access

Identity and mechanism

TB-500 questions cluster around one theme: what is actually known about the fragment versus its parent protein. Each answer below states the finding first, then the caveat.

What is TB-500?

TB-500 is the synthetic, N-acetylated heptapeptide Ac-LKKTETQ, corresponding to residues 17–23 — the actin-binding motif — of the 43-amino-acid protein thymosin beta-4 [5]. It is a synthetic construct supplied for research, not an endogenous molecule.

What does TB-500 stand for and what does TB stand for in TB-500?

TB references thymosin beta; the ‘500’ is a catalog number, not an acronym with an official expansion. TB-500 is a research and veterinary designation for the synthetic Ac-LKKTETQ fragment of thymosin beta-4, and the same heptapeptide also circulates under the label TB1000.

What is TB-500 used for in research?

It is studied as the actin-binding fragment of thymosin beta-4 in tissue-repair, wound-healing, muscle and ligament, cardiac, neurological, and angiogenesis models [5] — overwhelmingly using full-length thymosin beta-4, not the 7-mer.

How does TB-500 work?

It carries the LKKTETQ actin-binding motif of thymosin beta-4, which sequesters monomeric (G-) actin 1:1 to regulate cytoskeletal dynamics, cell migration, angiogenesis, and anti-inflammatory signaling in injury models [1]. Whether the isolated fragment reproduces these at research doses is unproven.

Recovery, healing, and effects

Does TB-500 work for muscle tears and recovery from exercise?

Muscle injury induces thymosin beta-4, which acts as a chemoattractant recruiting myoblasts to injured muscle in animal models [7]. Controlled human efficacy for the TB-500 fragment is not established.

Can TB-500 help with tendon injuries and ligament repair?

Thymosin beta-4 enhanced healing of medial collateral ligament injury in a rat model [8] — one of the few direct connective-tissue repair findings underpinning the athletic-recovery rationale. It is a rodent, parent-protein result.

How long does it take for TB-500 to work for injury healing?

No human injury-healing timeline is established for the fragment. In a rat wound model, full-length thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline [3] — a different molecule, tissue, and species.

Does TB-500 affect the heart?

In mice, thymosin beta-4 activated the PINCH-ILK-Akt survival pathway and improved cardiac function after coronary artery ligation [2]; a porcine ischemia-reperfusion study found no attenuation of injury, tempering the cardioprotection narrative.

Does TB-500 have neuroprotective effects on the brain?

In a rat embolic-stroke dose-response study, intraperitoneal thymosin beta-4 improved neurological function at 2 and 12 mg/kg but not at 18 mg/kg, with a modeled optimal dose near 3.75 mg/kg [4] — a non-monotonic result.

Does TB-500 promote angiogenesis and is that a safety concern?

Thymosin beta-4 induces VEGF in a HIF-1α-dependent manner and promotes endothelial migration [10]. This pro-angiogenic activity aids repair but is also the basis of the tumor-angiogenesis safety signal.

Does TB-500 increase hair growth?

Hair-follicle bulge stem cells are a documented target of thymosin beta-4 in rodent models [5]. This is a parent-protein finding and is not established for the TB-500 fragment in humans.

Does TB-500 reduce inflammation?

Thymosin beta-4 suppressed corneal NF-κB and, in vitro, has been tied to reduced inflammatory signaling [12] — a mechanistic basis reported for the full-length protein, not a demonstrated clinical effect of the fragment.

Safety and evidence

Does TB-500 cause cancer or promote tumor growth?

Thymosin beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis [13]. The same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression — a key safety consideration.

What are the side effects of TB-500?

Human safety data for the fragment are scarce; the principal documented concern is the tumor and angiogenesis signal associated with thymosin beta-4 [13], alongside unverified research-grade material quality. A 2026 review notes the potential for serious harm [14].

Are there any human clinical trials on TB-500?

There are no completed controlled clinical trials of the TB-500 fragment [13]. Human data exist only for full-length thymosin beta-4 — an intravenous Phase 1 safety and pharmacokinetics study [6] and topical ophthalmic RCTs.

What is the difference between TB-500 and BPC-157?

Both are research peptides studied for tissue repair; TB-500 is the Ac-LKKTETQ actin-binding fragment of thymosin beta-4 [5], while BPC-157 is a distinct gastric-derived pentadecapeptide. A 2026 Sports Medicine review lists both among unapproved musculoskeletal peptides [14].

How does TB-500 compare to other peptides for recovery and healing?

A 2026 Sports Medicine review concluded that many unapproved repair peptides show favorable tissue-repair outcomes in animal models, but that rigorous human safety data are scarce and they operate largely outside regulatory oversight [14].

Dosing context

How much TB-500 should be taken per week during a loading phase?

Community "loading then maintenance" protocols are not derived from controlled human trials and have no published clinical validation [13]; animal studies dosed full-length thymosin beta-4 by body weight in milligram-per-kilogram ranges [4].

How does subcutaneous vs intramuscular injection of TB-500 compare?

Rodent efficacy studies predominantly used intraperitoneal dosing [4]; subcutaneous and intramuscular are community research-use routes not validated in controlled human efficacy trials [13].

What is the half-life of TB-500 and how often should it be dosed?

No validated human pharmacokinetic half-life exists for the TB-500 heptapeptide [13]; in the intravenous full-length thymosin beta-4 Phase 1 study, half-life increased with dose, i.e. dose-proportional pharmacokinetics [6].